GH Research (GHRS) Cash from Operations Growth (1y) (2021 - 2025)
GH Research (GHRS) Cash from Operations Growth (1y) (2021 - 2025) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Ops. Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
723,416.35 Bn |
723,416.32 Bn |
- |
- |
| 2 |
Belite Bio |
57,340.00 Bn |
57,340.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
19,125.08 Bn |
19,125.08 Bn |
- |
60.84% |
| 4 |
Legend Biotech |
3,262.00 Bn |
3,261.71 Bn |
242.10 Mn |
85.14% |
| 5 |
Akari Therapeutics |
1,789.67 Bn |
1,789.67 Bn |
- |
-15.72% |
| 6 |
Evaxion A |
1,480.39 Bn |
1,480.37 Bn |
- |
- |
| 7 |
Psyence Biomedical |
241.78 Bn |
241.78 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
113.54 Bn |
106.29 Bn |
2.59 Bn |
74.39% |
| 9 |
Abivax |
94.26 Bn |
94.26 Bn |
- |
- |
| 10 |
GH Research |
9.73 Bn |
9.63 Bn |
- |
-22.02% |
| Date | Value |
|---|
| Dec 31, 2025 |
-22.02% |
| Sep 30, 2025 |
-24.46% |
| Jun 30, 2025 |
0.10% |
| Mar 31, 2025 |
-1.83% |
| Dec 31, 2024 |
-28.43% |
| Sep 30, 2024 |
-23.97% |
| Jun 30, 2024 |
-33.41% |
| Mar 31, 2024 |
-45.04% |
| Dec 31, 2023 |
-44.36% |
| Sep 30, 2023 |
-37.30% |
| Jun 30, 2023 |
-64.47% |
| Mar 31, 2023 |
-21.95% |
| Dec 31, 2022 |
-82.29% |
| Sep 30, 2022 |
12.65% |
| Jun 30, 2022 |
-333.63% |
| Mar 31, 2022 |
-452.07% |
| Dec 31, 2021 |
-2,428.19% |
| Sep 30, 2021 |
-11,861.04% |
